Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicinal composition for preventing or treating hypertensive obese patient and application thereof

A high blood pressure and composition technology, applied in the field of western medicine compound prescription, can solve the problems of poor response, unable to reduce blood pressure, unsatisfactory weight loss effect, etc., and achieve the effects of reducing adverse reactions, reducing adverse drug reactions, and reducing the dosage used

Active Publication Date: 2013-04-10
南通金羽禽业发展有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many hypertensive and obese patients try to lose weight and lower blood pressure by taking weight-loss drugs, but the efficacy of weight loss is very dissatisfied, and blood pressure cannot be lowered. The reason may be that many obese people respond poorly to various weight-loss drugs
[0005] All in all, there is currently no very effective drug for the treatment of hypertensive and obese patients in clinical practice. Therefore, finding effective intervention drugs has very important theoretical significance and application value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for preventing or treating hypertensive obese patient and application thereof
  • Medicinal composition for preventing or treating hypertensive obese patient and application thereof
  • Medicinal composition for preventing or treating hypertensive obese patient and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Effect of Valsartan / Orlistat Compound on Obese and Hypertensive Rats

[0025] 1. Preparation of animal models

[0026] 70 6-week-old male essential hypertensive rats (SHR), weighing 140-160 g, were randomly divided into two groups: 10 normal feed group (normal group) and 60 nutritional feed group. Both groups had free access to food and water. After 90 days (modeling period), the rats whose body weight in the nutrient feed group exceeds the average body weight of the normal food group by 25% are the hypertensive and obese rat models. Among them, the nutritious feed is prepared according to the following formula: 60% common feed, 12% lard, 5% sucrose, 5% milk powder, 5% peanut, 10% egg, 1% sesame oil, and 2% salt. Refer to Sun Zhi's "Experimental Research on Nutritional Obesity Animal Models".

[0027] 2. Grouping and administration

[0028] The rat model was randomly divided into the following 6 groups: model group, orlistat group, valsartan group, compoun...

Embodiment 2

[0047] Example 2 Effect of Telmisartan / Orlistat Compound on Obesity and Hypertensive Rats

[0048]1. Preparation of animal models

[0049] Sixty 6-week-old male essential hypertensive rats (SHR), weighing 140-160 g, were randomly divided into two groups: 10 normal feed groups (normal group) and 50 nutritional feed groups. Both groups had free access to food and water. After 90 days (modeling period), the rats whose body weight in the nutrient feed group exceeds the average body weight of the normal food group by 25% are the hypertensive and obese rat models. Among them, the nutritious feed is prepared according to the following formula: 60% common feed, 12% lard, 5% sucrose, 5% milk powder, 5% peanut, 10% egg, 1% sesame oil, and 2% salt. Refer to Sun Zhi's "Experimental Research on Nutritional Obesity Animal Models".

[0050] 2. Grouping and administration

[0051] The rat model was randomly divided into the following 5 groups: model group, orlistat group, telmisartan grou...

Embodiment 3

[0070] The preparation of embodiment 3 valsartan / orlistat compound tablet

[0071] Prescription composition:

[0072]

[0073] Preparation Process:

[0074] Weigh orlistat and valsartan according to the prescription quantity, use starch and microcrystalline cellulose as filler, low-substituted hydroxypropyl cellulose as disintegrant, 15% starch slurry as binder, and magnesium stearate as The lubricant is granulated in one step in a fluidized bed, and then compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition for preventing or treating a hypertensive obese patient and application thereof. The active component of the composition consists of a losartan medicament and orlisat, wherein the losartan medicament is selected from valsartan or telmisartan. The western medicine compound can treat the hypertensive obese patient synergetically and reduce adverse effects of the medicament at the same time.

Description

technical field [0001] The invention relates to a compound western medicine, in particular to a pharmaceutical composition for preventing or treating obese patients with high blood pressure and its use, and belongs to the technical field of compound western medicine. Background technique [0002] Obesity accompanied by hypertension is a common clinical problem. Epidemiological studies have shown that obesity is one of the important risk factors for hypertension. The relative risk of hypertension increases significantly with the increase of body mass index. At the same time, obesity and Hypertension and both are important risk factors for cardiovascular disease, and when the two exist at the same time, the risk factors are more serious. According to statistics, the incidence of hypertension is 10-15%, of which 10-40% is accompanied by obesity or overweight. The incidence of hypertension in obese people is significantly higher than that in non-obese people, which is a fact co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/41A61K31/365A61K31/4184A61P9/12A61P3/04
Inventor 侯广臣
Owner 南通金羽禽业发展有限公司